{"status": "Ok", "redirect_url": "https://www.benitec.com/for-investors/news-events/press-releases/detail/146/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting", "message": "News view counter 684631 successfully enlarged"}